CLOSED WORKSHOP - BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE
Co-chairs: D. Rossi, Bellinzona (Switzerland), W.H. Wilson, Bethesda, MD (USA) and E. Zucca, Bellinzona (Switzerland)
Organized in co-operation with the American Association for Cancer Research – AACR and the European School of Oncology – ESO
and with the endorsement of the Leukemia & Lymphoma Society - LLS
by invitation only

WORKSHOP – NEW GUIDELINES FROM THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP - ILROG
Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG
open to all 15-ICML attendees

PART 1 – NEW GUIDELINES FROM ILROG
Chair: L. Specht, Copenhagen (Denmark)

15:00
RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
A. Ng, Boston, MA (USA)

15:15
SOLITARY PLASMACYTOTMA AND MULTIPLE MYELOMA
R. Tsang, Toronto (Canada)

15:30
IMAGING IN RADIATION THERAPY FOR LYMPHOMA
G. Mikhaeel, London (UK)

15:45
PROTON THERAPY FOR MEDIASTINAL LYMPHOMAS
B.S. Dabaja, Houston, TX (USA)

16:00
DISCUSSION

16:15
COFFEE BREAK inside Aula Magna (USI Università), for attendees

PART 2 – PANEL DISCUSSION
Led by J. Plastaras, Philadelphia, PA (USA)

16:30
FUTURE GUIDELINES TO BE DEVELOPED; ISSUES TO BE CONSIDERED IN ILROG GUIDELINES

16:50
HOW TO DISSEMINATE AND USE ILROG GUIDELINES
**Wednesday, June 19, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Article Nr</th>
<th>Title</th>
<th>Speaker, City, Country</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:15</td>
<td>“MEET THE PROFESSOR” SESSIONS</td>
<td>EB09</td>
<td>MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?</td>
<td>S.V. Rajkumar, Rochester, MN (USA)</td>
<td>repeated on Thursday, June 20, in Room B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room A</td>
<td>THE MODERN APPROACH TO MANTLE CELL LYMPHOMA</td>
<td>S. Rule, Plymouth (UK)</td>
<td>repeated on Thursday, June 20, in Room A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cinema Corso</td>
<td>MANAGING THE TOXICITIES OF CAR T-CELL THERAPY</td>
<td>S.S. Neelapu, Houston, TX (USA)</td>
<td>repeated on Friday, June 21, in Auditorium (USI Università)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Auditorium</td>
<td>PCNSL, A CURABLE DISEASE</td>
<td>T.T. Batchelor, Boston, MA (USA)</td>
<td>repeated on Thursday, June 20, in Cinema Corso</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aula Magna</td>
<td>WHAT WE SHOULD KNOW ABOUT NK/T-CELL LYMPOMAS</td>
<td>W. Zhao, Shanghai (China)</td>
<td>offered only once</td>
</tr>
<tr>
<td>09:00 – 12:00</td>
<td>POSTER SESSION SET UP</td>
<td>Marquee</td>
<td>5 parallel sessions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 – 10:15</td>
<td></td>
<td>Room A</td>
<td>DOUBLE HIT LYMPHOMA, SO WHAT?</td>
<td>A. Davies, Southampton (UK)</td>
<td>repeated on Friday, June 21, in Room B</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Room B</td>
<td>HOW TO APPROACH CLL IN CLINICAL PRACTICE</td>
<td>M. Hallek, Cologne (Germany)</td>
<td>repeated on Friday, June 21, in Room A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cinema Corso</td>
<td>LIQUID BIOPSY IN NON-HODGKIN’S LYMPHOMA</td>
<td>W.H. Wilson, Bethesda, MD (USA)</td>
<td>repeated on Thursday, June 20, in Auditorium (USI Università)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Auditorium</td>
<td>CUTANEOUS LYMPHOMAS</td>
<td>W. Kempf, Zurich (Switzerland)</td>
<td>repeated on Friday, June 21, in Cinema Corso</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aula Magna</td>
<td>BREAST IMPLANT ASSOCIATED ALC AND OTHER RARE T-CELL LYMPHOMAS</td>
<td>L. de Leval, Lausanne (Switzerland)</td>
<td>offered only once</td>
</tr>
<tr>
<td>10:15 – 10:35</td>
<td>COFFEE BREAK</td>
<td>Marquee, Cinema Corso, USI Università</td>
<td>5 parallel sessions</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
10:35 – 12:00

EDUCATIONAL SYMPOSIA

2 parallel sessions

Room A, Cinema Corso, Auditorium and Aula Magna (USI Università)

TREATING HODGKIN LYMPHOMA IN THE NEW MILLENNIUM
Chair: A. Engert, Cologne (Germany)

EB13 OPTIONS FOR FIRST LINE THERAPY OF HODGKIN LYMPHOMA
P.W.M. Johnson, Southampton (UK)

EB14 RELAPSED AND REFRACTORY DISEASE
A.S. LaCasce, Boston, MA (USA)

EB15 TREATMENT OF ELDERLY HODGKIN LYMPHOMA PATIENTS
A. Engert, Cologne (Germany)

Room B and Marquee

NEW DRUGS FOR NON-HODGKIN LYMPHOMA: BEYOND CHEMOTHERAPY
Chair: G. Salles, Lyon (France)

EB16 CAR T CELL THERAPY: FULL SPEED AHEAD
R.J. Brentjens, New York, NY (USA)

EB17 NEW DRUGS FOR OLD TARGETS
G. Salles, Lyon (France)

EB18 NEW DRUGS FOR NEW TARGETS
A. Younes, New York, NY (USA)

12:00 – 17:00

Abstract Nr

POSTER SESSION

136 - 159 BIOLOGY AND PATHOLOGY
160 - 169 CLL
170 - 183 INDOLENT LYMPHOMAS
184 - 191 MANTLE CELL LYMPHOMAS
192 - 206 AGGRESSIVE LYMPHOMAS
207 - 217 EXTRANODAL LYMPHOMAS
218 - 233 PTCL AND NK/T CELL LYMPHOMAS
234 - 245 HODGKIN LYMPHOMAS
246 - 262 IMMUNOTHERAPY
263 - 285 NOVEL TREATMENTS

12:00 – 13:00

LUNCH TIME AND POSTER VIEWING

13:00 – 14:00

Room A, B, Marquee, Cinema Corso, Auditorium and Aula Magna (USI Università)

OPENING OF THE CONFERENCE

WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)

HENRY KAPLAN MEMORIAL LECTURE AND SAN SALVATORE FOUNDATION PRIZE

Introduction to San Salvatore Foundation: S. Coduri, Lugano (Switzerland)
Laudatio: R. Stahel, Zurich (Switzerland)

001 NEXT GENERATION CAR T CELLS FOR LYMPHOMA AND BEYOND
C.H. June, Philadelphia, PA (USA)

14:00 – 15:25

Room A, B, Marquee, Cinema Corso, Auditorium and Aula Magna (USI Università)

PLENARY SESSION

Co-chairs: J.O. Armitage, Omaha, NE (USA) and F. Cavalli, Bellinzona (Switzerland)
14:00  004  IDENTIFYING MUTATIONS ENRICHED IN RELAPSED-REFRACTORY DLBCL TO DERIVE GENETIC FACTORS UNDERLYING TREATMENT RESISTANCE
C. Rushton, Burnaby, B.C (Canada)

14:15  005  ROBUST: FIRST REPORT OF PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP (R2-CHOP) VS PLACEBO/R-CHOP IN PREVIOUSLY UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA
U. Vitolo, Turin (Italy)

14:30  006  ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP
G.S. Nowakowski, Rochester, MN (USA)

14:45  Discussant for presentations 004, 005 and 006: M.A. Shipp, Boston, MA (USA)

15:00  007  IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL
P. Langerbeins, Cologne (Germany)

15:15  Discussant for presentation 007: S.M. O’Brien, Irvine, CA (USA)

14:50 – 15:50  COFFEE BREAK

15:50 – 16:50  AACR-ICML JOINT SESSION - THE ROLE OF NON-CLINICAL MODELS AS BRIDGES TO EARLY CLINICAL TRIALS
Co-chairs: M. Foti, Philadelphia, PA (USA) and B. Nadel, Marseille (France)

15:50  008  DESIGNER ORGANOIDS FOR MODELING EPIGENETICS, SIGNALING, AND THERAPIES IN LYMPHOMA
A. Singh, New York, NY (USA)

16:10  009  MOUSE PDX AS NON-CLINICAL MODELS FOR LYMPHOMA
A. Louissaint, Boston, MA (USA)

16:30  010  ADVANCING OUR UNDERSTANDING AND TREATMENT OF LYMPHOMA WITH SPONTANEOUS CANINE MODELS
L. Aresu, Turin (Italy)

17:05 – 18:05  “FOCUS ON…” SESSIONS
5 parallel sessions

Room A  MANTEL CELL LYMPHOMA
Chair: J.P. Leonard, New York, NY (USA)

17:05  011  COMBINATION OF IBRUTINIB WITH RITUXIMAB (IR) IS HIGHLY EFFECTIVE IN PREVIOUSLY UNTREATED ELDERLY (>65 YEARS) PATIENTS (PTS) WITH MANTLE CELL LYMPHOMA (MCL) – PHASE II TRIAL
P. Jain, Houston, TX (USA)

17:15  012  IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL)
M. Wang, Houston, TX (USA)
17:25 013 AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION-FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA
A. Zoellner, Munich (Germany)

17:35 014 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY
S. Le Gouill, Nantes (France)

17:45 015 ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Y. Song, Beijing (China)

17:55 016 OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY
C. Visco, Verona (Italy)

Room B

PET IMAGING
Chair: B.D. Cheson, Washington, D.C. (USA)

17:05 017 A GENE EXPRESSION-BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD
B. Donati, Reggio Emilia (Italy)

17:15 018 PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)-POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION
M. Novo, Rochester, MN (USA)

17:25 019 HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY
L. Vercellino, Paris (France)

17:35 020 BASELINE TOTAL METABOLIC TUMOUR VOLUME IS HIGHLY PROGNOSTIC FOR REFRACTORINESS TO IMMUNOCHEMOTHERAPY IN DLBCL: AN ANALYSIS OF THE PHASE 3 GOYA TRIAL
M. Trněný, Prague (Czech Republic)

17:45 021 RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY
S. Chauvie, Cuneo (Italy)

17:55 022 PROGNOSTIC VALUE OF PRE-TREATMENT PET SCAN IN PATIENTS WITH FOLLICULAR LYMPHOMA RECEIVING FRONTLINE THERAPY
P. Strati, Houston, TX (USA)

Cinema Corso

PEDIATRIC LYMPHOMA
Chair: W. Wössmann, Hamburg (Germany)

17:05 023 NON-HODGKIN LYMPHOMA IN ADOLESCENT AND YOUNG ADULTS - A NATIONAL PROSPECTIVE POPULATION-BASED STUDY
R. Carr, London (UK)
INCLUSION OF A PEDIATRIC PERSPECTIVE INTO RECOMMENDATIONS FOR THE INITIAL EVALUATION AND STAGING OF HODGKIN LYMPHOMA: A CALL TO ACTION FROM THE INTERNATIONAL SEARCH WORKING GROUP
J. Flerlage, Memphis, TN (USA)

SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
J. Flerlage, Memphis, TN (USA)

RESPONSE-ADAPTED TREATMENT WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN YOUNG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 744 SUBGROUP ANALYSES
K.M. Kelly, Buffalo, NY (USA)

IBRUTINIB + CHEMOIMMUNOTHERAPY (CIT) FOR RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL) IN CHILDREN (SPARKLE TRIAL): INITIAL SAFETY, PK, AND EFFICACY
A. Burke, Cambridge (UK)

CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR REFRACTORY AND RELAPSED BURKITT’S LYMPHOMA, EARLY RESPONSE IN PEDIATRIC PATIENTS
W.Q. Zhang, Beijing (China)

RESULTS FROM SINGLE AGENT TRIALS
Chair: C. Thieblemont, Paris (France)

PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
K.A. Rogers, Columbus, OH (USA)

RAPID AND DURABLE RESPONSES WITH THE SYK/JAK INHIBITOR CERDULATINIB IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA—ALONE OR IN COMBINATION WITH RITUXIMAB
S.D. Smith, Seattle, WA (USA)

A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
N. Kalakonda, Liverpool (UK)

TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
T.E. Witzig, Rochester, MN (USA)

DUVELISIB, AN ORAL DUAL PI3K-δ,γ INHIBITOR, EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) PERIPHERAL T-CELL LYMPHOMA: RATIONALE FOR THE PHASE 2 PRIMO TRIAL
S.M. Horwitz, New York, NY (USA)

EFFICACY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH LESS ADVANCED MYCOSIS FUNGOIDES: RESULTS FROM THE MAVORIC STUDY
J. Scarisbrick, Birmingham (UK)
Aula Magna
(USI Università)

ONGOING TRIALS
Chair: J.M. Vose, Omaha, NE (USA)

17:05 OT01 NCRI PETReA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA
A.R. Pettitt, Liverpool (UK)

17:15 OT02 POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R-CHP VERSUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL
H. Tilly, Rouen (France)

17:25 OT03 PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R-CHOP VS PLACEBO/R-CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
J. Zhu, Beijing (China)

17:35 OT04 THE DIAL STUDY (DUAL IMMUNOMODULATION IN AGGRESSIVE LYMPHOMA): RANDOMIZED PHASE 2 TRIAL OF VARLILUMAB PLUS NIVOLUMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS
J.C. Villasboas, Rochester, MN (USA)

17:45 OT05 ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRIStINE AND PREDNISOLONE (R-CHOP) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
T. Cummin, Southampton (UK)

17:55 OT06 TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA
P. Porcu, Philadelphia, PA (USA)
### Thursday, June 20, 2019

| 08:00 – 08:45 | **MEET THE PROFESSOR SESSIONS**  
5 parallel sessions |
| Room A | EB10 | THE MODERN APPROACH TO MANTLE CELL LYMPHOMA  
S. Rule, Plymouth (UK) |
| Room B | EB09 | MULTIPLE MYELOMA: EVERY YEAR A NEW STANDARD?  
S.V. Rajkumar, Rochester, MN (USA) |
| Cinema Corso | EB01 | PCNSL, A CURABLE DISEASE  
T.T. Batchelor, Boston, MA (USA) |
| Auditorium (USI Università) | EB11 | LIQUID BIOPSY IN NON-HODGKIN’S LYMPHOMA  
W.H. Wilson, Bethesda, MD (USA) |
| Aula Magna (USI Università) | EB04 | NEW TREATMENT OPTIONS IN HAIRY CELL LEUKEMIA WITH FOCUS ON BRAF INHIBITORS  
B. Falini, Perugia (Italy)  
*offered only once* |

| 09:00 – 17:00 | **POSTER SESSION** |

| 09:00 – 10:30 | **“CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)**  
4 parallel sessions |
| Room A | DLBCL  
Chair: L.H. Sehn, Vancouver, B.C. (Canada)  
Discussants: E. Giné Soca, Barcelona vs J.R. Westin, Houston |
| Cinema Corso | HODGKIN LYMPHOMA  
Chair: A.S. LaCasce, Boston, MA (USA)  
Discussants: A.M. Sureda Balari, Barcelona vs H.J. Lee, Houston |
| Auditorium (USI Università) | RADIOTherapy FOR LYMPHOMAS  
Chair: L. Specht, Copenhagen (Denmark)  
Discussants: T. Illidge, Manchester (UK) vs B.S. Dabaja, Houston |
| Aula Magna (USI Università) | DIFFICULT PATHOLOGICAL CASES  
Chair: M. GhieLMini, Bellinzona (Switzerland)  
Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland) and P. Gaulard, Paris (France)  
Discussants: A. Lopez-Guillermo, Barcelona vs R. Hagemeister, Houston |

| 09:00 – 10:30 | **SESSION 1 – DLBCL: BIOLOGY**  
Co-chairs: R. Dalla-Favera, New York, NY (USA) and R. Küppers, Essen (Germany) |
| Room B and Marquee | Abstract Nr 035 | AN AUTOCHTHONOUS MOUSE MODEL OF MYD88 P.L265P- AND BCL2-DRIVEN DIFFUSE LARGE B CELL LYMPHOMA  
G. Knittel, Cologne (Germany) |
| Room B and Marquee | 09:00 | 036 | CRYPTIC MYC AND BCL2 REARRANGEMENTS ARE AMONG A RANGE OF GENETIC MECHANISMS UNDERLYING THE DOUBLE HIT SIGNATURE IN NON-DUlle DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA  
L.K. Hilton, Burnaby, B.C. (Canada) |
FUNCTIONAL CHARACTERIZATION OF NFKBIZ 3′ UTR MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA
S.E. Arthur, Burnaby, B.C. (Canada)

THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
G. Sartori, Bellinzona (Switzerland)

TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA
T. Roider, Heidelberg (Germany)

THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR-SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA
S. Napoli, Bellinzona (Switzerland)

INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT
L. Ceriani, Bellinzona (Switzerland)

SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
J.R. Westin, Houston, TX (USA)

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY
P. Lugtenburg, Rotterdam (Netherlands)

IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE POPULATION-BASED STUDY
T. Shree, Stanford, CA (USA)

INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT
L. Ceriani, Bellinzona (Switzerland)

SMART START: RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE PRIOR TO COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA
J.R. Westin, Houston, TX (USA)

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON-NORDIC LYMPHOMA GROUP PHASE III STUDY
P. Lugtenburg, Rotterdam (Netherlands)

IMPAIRED IMMUNE HEALTH IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A LARGE POPULATION-BASED STUDY
T. Shree, Stanford, CA (USA)

LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees

GIANNI BONADONNA MEMORIAL LECTURE

GIANNI BONADONNA MEMORIAL LECTURE

PRECISION EPIGENETIC THERAPY FOR B-CELL LYMPHOMA
A.M. Melnick, New York, NY (USA)
13:45 – 15:15
Room A, B, Marquee, Cinema Corso, Auditorium and Aula Magna (USI Università)

SESSION 3 – CLL
Chairs: J.F. Seymour, Melbourne (Australia) and M. Hallek, Cologne (Germany)

13:45 045
INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A)
A. Condoluci, Bellinzona (Switzerland)

14:00 046
FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES
K. Fischer, Cologne (Germany)

14:15 047
GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY
E. Tausch, Ulm (Germany)
Best abstract submitted by a young investigator/travel grant recipient

14:30 048
ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB (IR) OR BENDAMUSTINE (BR) BY INVESTIGATOR CHOICE IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: PHASE 3 ASCEND STUDY
P. Ghia, Milan (Italy)

14:45 049
ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
W. Xu, Nanjing (China)

15:00 050
A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
A.R. Mato, New York, NY (USA)

15:15 – 15:40
Marquee

15:40 – 16:55
2 parallel sessions
Room A, Cinema Corso, Auditorium and Aula Magna (USI Università)

SESSION 4 – TREATMENT WITH NOVEL ANTIBODIES
Co-chairs: D.G. Maloney, Seattle, WA (USA) and P.L. Zinzani, Bologna (Italy)

15:40 051
THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
R.H. Advani, Stanford, CA (USA)

15:55 052
CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
M.S. Topp, Würzburg (Germany)
CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
M.J. Dickinson, Melbourne (Australia)

ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT-402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
J. Radford, Manchester (UK)

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT-301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
G. Collins, Oxford (UK)

SESSION 5 – T-CELL LYMPHOMAS
Room B and Marquee
Co-chairs: S. Luminari, Reggio Emilia (Italy) and K.J. Savage, Vancouver, B.C. (Canada)

RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.
P. Ghione, New York, NY (USA)

AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY
M. Lopez-Parra, Salamanca (Spain)

FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY
O. Tournilhac, Clermont-Ferrand (France)

TREATMENT BENEFIT ASSOCIATING WITH NON-ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE
S. Qi, Beijing (China)

SINTILIMAB FOR RELAPSED/REFRACTORY (R/R) EXTRANODAL NK/T CELL LYMPHOMA (ENKTL): A MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL (ORIENT-4)
R. Tao, Shanghai (China)

“FOCUS ON…” SESSIONS
5 parallel sessions

CLL AND MORE
Chair: D. Rossi, Bellinzona (Switzerland)

FIVE-YEAR FOLLOW-UP OF FIRST-LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
A. Tedeschi, Milan (Italy)

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL
O. Al-Sawaf, Cologne (Germany)
17:25  063  IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY J. Wu, San Francisco, CA (USA)

17:35  064  AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/REFRACTORY CLL S. Handunnetti, Melbourne (Australia)

17:45  065  TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA T. Siddiqi, Duarte, CA (USA)

17:55  066  THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL E. Tiacci, Perugia (Italy)

Room B

CHEMOTHERAPY-FREE STRATEGIES
Chair: J.W. Friedberg, Rochester, NY (USA)

17:05  067  PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY-FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK) A. Moccia, Bellinzona (Switzerland)

17:15  068  EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL F. Morschhauser, Lille (France)

17:25  069  AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS J.P. Leonard, New York, NY (USA)

17:35  070  INTERIM ANALYSIS OF PHASE IIIB MAGNIFY STUDY OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA J. Sharman, Eugene, OR (USA)

17:45  071  RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY M.H. Delfau-Larue, Creteil (France)

17:55  072  SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS. A. Stathis, Bellinzona (Switzerland)

Cinema Corso

NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS
Chair: A. Davies, Southampton (UK)

17:05  073  PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER’S TRANSFORMATION A.R. Mato, New York, NY (USA)
17:15 074 PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL
S.D. Smith, Seattle, WA (USA)

17:25 075 ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
C.S. Tam, Melbourne (Australia)

17:35 076 A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW-GRADE B-CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS
T. Shree, Stanford, CA (USA)

17:45 077 EXTENDED FOLLOW-UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E4412)
C. Diefenbach, New York, NY (USA)

17:55 078 HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS.
T.E. Cummin, Southampton (UK)

Auditorium (USI Università)  
NON-CLINICAL NEW DRUGS
Chair: L. Pasqualucci, New York, NY (USA)

17:05 079 FIRST-IN-CLASS HAT ACTIVATOR HIGHLY SYNERGISTIC WITH PAN-HDAC INHIBITOR ROMIDEPSIN LEADING TO PROFOUND HISTONE ACETYLATION CYTOTOXICITY
Y. Liu, New York, NY (USA)

17:15 080 COPANLISIB AND VOLASERTIB OVERCOME IBRUTINIB-VENETOCLAX RESISTANCE VIA TARGETING PI3K-AKT SIGNALING AND G2/M CELL CYCLE TRANSITION IN MANTLE CELL LYMPHOMA
R. Zhang, Houston, TX (USA)

17:25 081 THE LANDSCAPE OF DRUG PERTUBATION EFFECTS IN LEUKEMIA AND LYMPHOMA
T. Zenz, Zurich (Switzerland)

17:35 082 DISCOVERY OF A NOVEL, POTENTIAL FIRST-IN-CLASS MALT1 PROTEASE INHIBITOR FOR THE TREATMENT OF B CELL LYMPHOMAS
U. Philippar, Bersee (Belgium)

17:45 083 KYM-001, A FIRST-IN-CLASS ORAL IRAK4 PROTEIN DEGRADER, INDUCES TUMOR REGRESSION IN XENOGRAFT MODELS OF MYD88-MUTANT ABC DLBCL ALONE AND IN COMBINATION WITH BTK INHIBITION
J. Kelleher, Cambridge, MA (USA)

17:55 084 THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION
C. Tarantelli, Bellinzona (Switzerland)
HIGH RISK LARGE B-CELL LYMPHOMAS

Chair: L.H. Sehn, Vancouver, B.C. (Canada)

17:05 085 EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV-SPECIFIC CTL AND IBRUTINIB THERAPY
M.K. Gandhi, Brisbane (Australia)

17:15 086 YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS
S. Leppä, Helsinki (Finland)

17:25 087 SAFETY AND EFFICACY OF THE PD-L1 INHIBITOR DURVALUMAB WITH R-CHOP OR R2-CHOP IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH-RISK DLBCL
G.S. Nowakowski, Rochester, MN (USA)

17:35 088 INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE-ADJUSTED R-EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC-043)
M.S. Davids, Boston, MA (USA)

17:45 089 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R-CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY
F. Morschhauser, Lille (France)

17:55 090 CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES
E.A. Chong, Philadelphia, PA (USA)
Friday, June 21, 2019

08:00 – 08:45

**MEET THE PROFESSOR SESSIONS**

*5 parallel sessions*

**Room A**

**EB05**

**HOW TO APPROACH CLL IN CLINICAL PRACTICE**

M. Hallek, Cologne (Germany)

**Room B**

**EB02**

**DOUBLE HIT LYMPHOMA, SO WHAT?**

A. Davies, Southampton (UK)

**Cinema Corso**

**EB06**

**CUTANEOUS LYMPHOMAS**

W. Kempf, Zurich (Switzerland)

**Auditorium**

**EB07**

**MANAGING THE TOXICITIES OF CAR T-CELL THERAPY**

S.S. Neelapu, Houston, TX (USA)

**Aula Magna**

**EB08**

**RARE B CELL LYMPHOMAS IN CHILDREN AND ADOLESCENTS**

L. Quintanilla-Martinez de Fend, Tübingen (Germany) and W. Wössmann, Hamburg (Germany)

*offered only once*

09:00 – 18:30

**Marquee**

**POSTER SESSION**

09:00 – 10:30

**“CASE DISCUSSION” SESSIONS: Spain vs Texas (USA)**

*3 parallel sessions*

**Room A**

**FL/ INDOLENT LYMPHOMA**

Chair: S. Rule, Plymouth (UK)

Discussants: M. Provencio Pulla, Madrid vs L.J. Nastoupil, Houston

**Cinema Corso**

**CLL**

Chair: S. O’Brien, Irvine, CA (USA)

Discussants: J. Delgado, Barcelona vs P.A. Thompson, Houston

**Aula Magna**

**PTCL**

Chair: K.J. Savage, Vancouver, B.C. (Canada)

Discussants: A. Martin, Salamanca vs N.H. Fowler, Houston

09:00 – 10:30

**Room B and Marquee**

**SESSION 6 – LYMPHOMA PATHOLOGY**

Co-chairs: K. Ohshima, Kurume (Japan) and E. Campo, Barcelona (Spain)

09:00

**091**

**DIAGNOSIS AND CLASSIFICATION ASSISTANCE FROM LYMPHOMA MICROSCOPIC IMAGES USING DEEP LEARNING**

P. Brousset, Toulouse (France)

09:15

**092**

**INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL.**

S.A. Pileri, Milan (Italy)

09:30

**093**

**CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B-CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL**

S. Balasubramanian, San Diego CA (USA)
LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA
S. Araf, London (UK)

DEFINING BURKITT-LIKE LYMPHOMA WITH 11Q ABERRATION IN A SPECIALISED UK HAEMATO Pathology DIAGNOSTIC SERVICE
S. Barrans, Leeds (UK)

GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA
L. Quintanilla-Martinez de Fend, Tübingen (Germany)

WORKSHOP – CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES
Organized in collaboration with the International Lymphoma Radiation Oncology Group - ILROG
open to all 15-ICML attendees

Part 1: FRACTIONATION ISSUES IN RADIOTHERAPY OF LYMPHOMAS
Chair: M.K. Gospodarowicz, Toronto, ON (Canada)

DOSE PER FRACTION, RESPONSE, LATE EFFECTS RELATIONSHIP IN LYMPHOMAS
R. Hoppe, Stanford, CA (USA)

OPTIMAL DOSE FRACTIONATION FOR INDOLENT AND AGGRESSIVE LYMPHOMAS
P. Hoskin, London and Manchester (UK)

OPTIMAL DOSE FRACTIONATION IN HODGKIN LYMPHOMAS
C. Baues, Cologne (Germany)

COFFEE BREAK inside Auditorium (USI Università), for attendees

Part 2: RADIOTHERAPY IN THE ELDERLY LYMPHOMA PATIENT
LYMPHOMA IN THE ELDERLY - SCOPE OF THE PROBLEMS
I. Glimelius, Uppsala (Sweden)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: INDOLENT LYMPHOMAS
U. Ricardi, Turin (Italy)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: AGGRESSIVE LYMPHOMA
J. Yahalom, New York, NY (USA)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: HODGKIN LYMPHOMA
L. Specht, Copenhagen (Denmark)

RADIOTHERAPY & LYMPHOMA IN THE ELDERLY: LATE EFFECTS
D. Hodgson, Toronto, ON (Canada)

QUESTIONS

COFFEE BREAK
**SESSION 7 – HODGKIN LYMPHOMA**

Co-chairs: R.H. Advani, Stanford, CA (USA) and T.A. Lister, London (UK)

11:00 097  STAGE I-II NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA IN THE MODERN ERA: A MULTI-INSTITUTIONAL EXPERIENCE OF ADULT PATIENTS BY ILROG
M.S. Binkley, Stanford, CA (USA)

11:15 098  NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2-YEAR FOLLOW-UP
S. Ansell, Rochester, MN (USA)

11:30 099  CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL
A. Gallamini, Nice (France)

11:45 100  COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF MULTIPLE TREATMENT STRATEGIES USING ABVD AND/OR BEACOPP IN THE TREATMENT OF ADVANCED-STAGE HODGKIN LYMPHOMA
A. Prica, Toronto, ON (Canada)

12:00 – 13:00  LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45  JOHN ULTMANN MEMORIAL LECTURE 🎤
sponsored by the European School of Oncology – ESO

Laudatio: J.M. Vose, Omaha, NE (USA)

P. Gaulard, Créteil (France)

13:45 – 15:00  4 parallel sessions

**SESSION 8 – FOLLICULAR LYMPHOMA**

Co-chairs: B.S. Kahl, St. Louis, MO (USA) and M. Herold, Erfurt (Germany)

13:45 101  PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY: A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL
S. Dirnhofer, Basel (Switzerland)

14:00 102  DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY
P. Perez Galan, Barcelona (Spain)

14:15 103  IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA
C.L. Batlevi, New York, NY (USA)

14:30 104  RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI
M. Federico, Modena (Italy)
14:45 105 INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
F. Morschhauser, Lille (France)

Room B and Marquee

SESSION 9 - EXTRANODAL LYMPHOMAS
Co-chairs: M.K. Gospodarowicz, Toronto, ON (Canada) and E. Zucca, Bellinzona (Switzerland)

13:45 106 INTEGRATIVE GENOMIC ANALYSIS IDENTIFIES KEY PATHOGENIC CONCEPTS IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
A. Mottok, Ulm (Germany)

14:00 107 OUTCOME OF PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA IN THE RITUXIMAB ERA: IMPACT OF A PET-GUIDED APPROACH
A. Hayden, Vancouver, B.C. (Canada)

14:15 108 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY
P.L. Zinzani, Bologna (Italy)

14:30 109 R-CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL
A.J. Ferreri, Milan (Italy)

14:45 110 POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) AFTER SOLID ORGAN TRANSPLANT (SOT): SURVIVAL AND PROGNOSTICATION AMONG 570 PATIENTS (PTS) TREATED IN THE MODERN ERA
D. Jagadeesh, Cleveland, OH (USA)

14:15 – 17:30

IBSA FOUNDATION SPECIAL FORUM - REVOLUTIONARY THERAPIES FOR CANCER
Chairmen: F. Cavalli, Bellinzona (Switzerland) and A. Alimonti, Bellinzona (Switzerland)
Organized by IBSA Foundation for Scientific Research
Open to all 15-ICML attendees, appreciated pre-registration at www.ibsafoundation.org (free session)

14:15 WELCOME AND INTRODUCTION
S. Misiti, IBSA Foundation
A. Alimonti, IBSA Foundation Scientific Board

14:30 mTOR SIGNALING IN GROWTH AND METABOLISM
M. Hall, Basel (Switzerland)

15:00 INNATE IMMUNITY, INFLAMMATION AND CANCER: FROM BENCH TO BEDSIDE
A. Mantovani, Milan (Italy), London (UK)

15:30 BUILDING NEXT GENERATION CAR T CELLS
C.H. June, Philadelphia, PA (USA)

16:00 FROM MOLECULAR ADDICTION TO IMMUNE ACTIVATION: REINVENTING THERAPIES FOR CANCER
S. Peters, Lausanne (Switzerland)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>UCLI-ICML JOINT SESSION – NEW DATA ON T-CELL AND OTHER LYMPHOMAS</td>
<td>Honorary Presidents: F. Cavalli, Bellinzona (Switzerland) and J. Ma, Harbin (China) Expected Presidents: W.J. Chng, Singapore (Singapore), J. M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China)</td>
<td>Aula Magna (USI Università)</td>
</tr>
<tr>
<td>14:20</td>
<td>20-YEAR SURVIVAL DATA ANALYSIS OF PTCL PATIENTS IN PEKING UNIVERSITY CANCER HOSPITAL</td>
<td>Y. Song, Beijing (China)</td>
<td>Aula Magna (USI Università)</td>
</tr>
<tr>
<td>14:45</td>
<td>DEVELOPING IMMUNOEPIGENETIC PLATFORMS FOR PTCL: LEVERAGING A LOGIC FOR PD1/PDL-1 INHIBITORS</td>
<td>O.A. O’Connor, New York, NY (USA)</td>
<td>Aula Magna (USI Università)</td>
</tr>
<tr>
<td>15:10</td>
<td>CLINICAL OUTCOME OF AN PROSPECTIVE, MULTICENTRE, RANDOMIZED, PHASE III NON-INFERIORITY CLINICAL TRIAL FOR PATIENTS WITH EXTRANODAL NK/T CELL LYMPHOMA TREATED BY P-GEMOX OR ASPAMETDEX</td>
<td>H. Huang, Guangzhou (China)</td>
<td>Aula Magna (USI Università)</td>
</tr>
<tr>
<td>15:35</td>
<td>COFFEE BREAK inside Aula Magna (USI Università), for attendees</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:55</td>
<td>NEW DATA IN THE MOLECULAR PATHOLOGY OF T CELL LYMPHOMAS</td>
<td>L. de Leval, Lausanne (Switzerland)</td>
<td>Marquee</td>
</tr>
<tr>
<td>16:20</td>
<td>DIFFUSE LARGE B-CELL LYMPHOMA: USING IMMUNE BIOMARKERS TO DEFINE NOVEL THERAPIES</td>
<td>W. Zhao, Shanghai (China)</td>
<td>Marquee</td>
</tr>
<tr>
<td>16:45</td>
<td>THE RELEVANCE OF OBSERVATIONAL REGISTRIES: THE CASE OF T CELL LYMPHOMA PROJECTS 1.0 AND 2.0</td>
<td>M. Federico, Modena (Italy)</td>
<td>Marquee</td>
</tr>
<tr>
<td>15:00</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>REPORT OF THE 15-ICML WORKSHOP</td>
<td>Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France)</td>
<td>Room A, B, Marquee and Cinema Corso</td>
</tr>
<tr>
<td>15:45</td>
<td>BRIDGING LIQUID BIOPSY INTO MANAGEMENT OF LYMPHOMA PATIENTS: DEVELOPMENT OF FRAMEWORKS FOR CLINICAL RESEARCH AND RECOMMENDATIONS FOR CLINICAL PRACTICE</td>
<td>W.H. Wilson, Bethesda, MD (USA)</td>
<td>Room A, B, Marquee and Cinema Corso</td>
</tr>
<tr>
<td>15:45</td>
<td>SESSION 10 – ADVANCES IN CAR-T CELL TREATMENT</td>
<td>Co-chairs: S.S. Neelapu, Houston, TX (USA) and G. Salles, Lyon (France)</td>
<td>Room A, B, Marquee and Cinema Corso</td>
</tr>
<tr>
<td>16:00</td>
<td>NOVEL BAFF-R CAR T-CELL THERAPY FOR CD19 ANTIGEN-LOSS RELAPSED B CELL TUMORS</td>
<td>L.W. Kwak, Duarte, CA (USA)</td>
<td>Room A, B, Marquee and Cinema Corso</td>
</tr>
<tr>
<td>16:15</td>
<td>PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION</td>
<td>C.L. Batlevi, New York, NY (USA)</td>
<td>Room A, B, Marquee and Cinema Corso</td>
</tr>
<tr>
<td>16:15</td>
<td>CD30-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR THERAPY OF HODGKIN LYMPHOMA (HL)</td>
<td>C.A. Ramos, Houston, TX (USA)</td>
<td>Room A, B, Marquee and Cinema Corso</td>
</tr>
</tbody>
</table>
16:30 120  DURABLE RESPONSES AFTER CD19-TARGETED CAR-T CELL IMMUNOTHERAPY WITH CONCURRENT IBRUTINIB FOR CLL AFTER PRIOR IBRUTINIB FAILURE  
J. Gauthier, Seattle, WA (USA)

16:45 121  HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR-T CELL IMMUNOTHERAPY  
A.V. Hirayama, Seattle, WA (USA)

17:00 122  SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY  
T. Siddiqi, Duarte, CA (USA)

17:15 – 17:35  SPECIAL LECTURE  
Room A, B, Marquee and Cinema 123  THE HIGH COST OF CANCER DRUGS: WHAT CAN WE DO?  
S.V. Rajkumar, Rochester, MN (USA)

17:35 – 18:30  FAREWELL APERO  
Marquee
Saturday, June 22, 2019

08:30 – 10:30  ESO – ESMIT Educational Session - PET-CT IN LYMPHOMA
Auditorium
(USI Università)
Chair: A.T. Lister, London (UK)
Organized by the European School of Oncology – ESO and the European School of Multimodality Imaging & Therapy – ESMIT
Open to all 15-iCML attendees

08:30
HOW TO INTERPRET PET-CT SCANS IN LYMPHOMAS: VISUAL AND FUNCTIONAL EVALUATION
M. Meignan, Creteil (France)

08:50
PET-BASED CLINICAL DECISIONS: WHERE DO WE STAND AND WHERE WE MAY GO
P.W.M. Johnson, Southampton (UK)

09:20
THE LUGANO CLASSIFICATION 5 YEARS AFTER: SHOULD WE CHANGE ANYTHING?
B.D. Cheson, Washington, D.C. (USA)

09:40
CHALLENGING CASES FROM THE ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
Presented by E. Zucca, Bellinzona (Switzerland) and L. Ceriani, Bellinzona (Switzerland)
Discussants: A.T. Lister, London (UK) and all faculty

08:30 – 10:00  SESSION 11 – NEW DRUG COMBINATIONS
Room A and B
Co-chairs: A. Younes, New York, NY (USA) and M. Dreyling, Munich (Germany)

08:30
124 PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND)
G. Salles, Lyon (France)

08:45
125 BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA
M. Dickinson, Melbourne (Australia)

09:00
126 POLATUZUMAB VEDOTIN (POLA) + OBiNUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS
A. McMillan, Nottingham (UK)

09:15
127 THE PI3KΔ INHIBITOR ME-401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)
A.D. Zelenetz, New York, NY (USA)

09:30
128 INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE
S.M. Ansell, Rochester, MN (USA)

09:45
129 TARGETING THE PERIPHERAL T-CELL LYMPHOMA (PTCL) EPIGENOME WITH ORAL 5-AZACYTIDINE AND ROMIDEPSIN: RESULTS AND CLINICAL-MOLECULAR CORRELATIONS FROM A PHASE 2 STUDY
L. Falchi, New York, NY (USA)
10:15 – 11:15  “FOCUS ON” SESSION - INDOLENT NON-FOLLICULAR LYMPHOMA
Room A and B

Chair: G.S. Nowakowski, Rochester, MN (USA)

10:15  130  EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT
A. Conconi, Ponderano (Italy)

10:25  131  INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE “IRIS” TRIAL
A.J. Ferreri, Milan (Italy)

10:35  132  MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY
A. Bruscaggin, Bellinzona (Switzerland)

10:45  133  UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY
P.L. Zinzani, Bologna (Italy)

10:55  134  IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY
J. Castillo, Boston, MA (USA)

11:05  135  IBRUTINIB MONOTHERAPY PRODUCES LONG-TERM DISEASE CONTROL IN PREVIOUSLY TREATED WALDENSTROM’S MACROGLOBULINEMIA: FINAL REPORT OF THE PIVOTAL TRIAL (NCT01614821)
S.P. Treon, Boston, MA (USA)

11:15 – 11:40  15-ICML HIGHLIGHTS  
Room A and B

“TAKE HOME MESSAGES”
J.W. Friedberg, Rochester, NY (USA)

11:40 – 11:50  CLOSURE AND FAREWELL
F. Cavalli, Bellinzona (Switzerland)

13:30 – 18:00  IV INTERNATIONAL WORKSHOP ON CANINE LYMPHOMA - HOW TO STAGE CANINE LYMPHOMA IN 2019
Room B

Co-chairs: L. Aresu, Turin (Italy); S. Comazzi, Milan (Italy); F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)
Organized by the European Canine Lymphoma Network
open to all 15-ICML attendees

This icon denotes presentations that will be audio- and video-recorded and available online, only for 15-ICML attendees, starting from July 2019, thanks to an unrestricted grant of a sponsor.

- Updated on May 22, 2019 -